

1 **The kinetic of SARS-CoV-2 antibody (Ab) decline determines the threshold for Ab persistence up to**
2 **one year**

3
4 Erika Garner-Spitzer¹, Angelika Wagner¹, Michael Kundi², Hannes Stockinger³, Anna Repic³, Anna-
5 Margarita Schoetta³, Venugopal Gudipati³, Johannes B. Huppa³, Renate Kunert⁴, Patrick Mayrhofer⁴,
6 Thomas R. Kreil⁵, Maria R. Farcet⁵, Eva Hoeltl⁶, Ursula Wiedermann^{1*}

7
8 1 Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and
9 Immunology, Medical University of Vienna, Vienna, Austria

10 2 Center for Public Health, Medical University of Vienna, Vienna, Austria

11 3 Institute for Hygiene and Applied Immunology, Centre for Pathophysiology, Infectiology and
12 Immunology, Medical University of Vienna, Vienna, Austria

13 4 Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna

14 5 Global Pathogen Safety, Baxter AG, a Takeda company, Vienna, Austria

15 6 Health Center Erste Bank, Erste Bank, Vienna, Austria

16

17 *Correspondence:

18 Univ. Prof. Ursula Wiedermann, MD, PhD

19 Institute of Specific Prophylaxis and Tropical Medicine

20 Centre for Pathophysiology, Infectiology and Immunology

21 Medical University of Vienna

22 Kinderspitalgasse 15, Vienna A-1090, Austria

23 Email: ursula.wiedermann@meduniwien.ac.at

24

25 **Abstract:** *Twelve subjects with positive SARS-CoV-2 neutralization test (NT) titers (>1:10) identified in*
26 *a seroprevalence study with 1655 working adults were followed up for one year. Here we report that*
27 *7 of these 12 individuals (58%) still had NT titers $\geq 1:50$, S1-specific IgG concentrations ≥ 50 BAU/ml*
28 *and $\geq 26\%$ ACE2 receptor binding inhibition, measured with surrogate virus NT one year after mild*
29 *COVID infection. Furthermore, NT₅₀ titers >1:10 and S1-specific IgG levels >60 BAU/ml present at*
30 *three months post-infection persisted at detectable levels for 1 year and correlated with circulating*
31 *S1-specific memory B-cells. Vaccine-induced SARS-CoV2 immune responses decline at similar rates as*
32 *those after infection; thus the describes threshold of 60 BAU/ml at three months post infection might*
33 *also be relevant for assessment of Ab persistence after vaccination.*

34







35 We recently reported in a longitudinal seroprevalence study conducted in a cohort of working adults
36 (n=1655) that neutralizing SARS-CoV-2 RBD-specific antibodies (Abs) persist for at least six months
37 independent of symptom severity (1). This study cohort was followed up to one year and twelve
38 selected subjects with positive neutralization test (NT) titers (>1:10) after infection were analyzed in
39 detail to assess their long-term Ab persistence, T cell reactivity and memory B cells over the course of
40 one year. SARS-CoV-2-specific Abs were evaluated quantitatively with neutralization test (NT₅₀ 1:x)
41 and S1 IgG ELISA (BAU/ml), and semi-quantitatively with surrogate-virus neutralization test (sVNT) (%
42 inhibition), RBD Ab ELISA (ratio) and NCP IgG ELISA (ratio) in serum samples obtained after mild
43 COVID infection and 3 months, 6 months and one year thereafter. On cellular level, S1-specific B
44 memory cells were quantified by flow-cytometry and cytokines were measured in culture

45 supernatants of S1-protein re-stimulated PBMC (see Supporting Information). The ethics committee
 46 of the Medical University of Vienna approved this monocentric study (EK 1438/2020, EK 1746/2020).
 47

48 **Results:**


49 Our results show that 7 of 12 subjects (58 %) still had NT titers $\geq 1:50$ (positive $>1:10$), S1-specific IgG
 50 concentrations ≥ 50 BAU/ml (seropositive >35.2 BAU/ml) and $\geq 26\%$ binding inhibition with sVNT (cut-
 51 off 20%) after one year (Fig.1 A-C). In all subjects RBD-specific Abs remained above the positive cut-
 52 off (ratio >1.1), while NCP-specific IgG declined below negative cut-off (ratio <0.8) between 6 months
 53 and one year (Fig.1 D, E).

54



80 **Figure 1 A-F:** Kinetics of SARS-CoV-2- specific Abs measured with different assays. A) NT₅₀ titers 1:x, B) S1-
81 specific IgG in BAU/ml, C) % inhibition in sVNT, D) RBD-specific Ab ratios and E) NCP-specific IgG ratios post-
82 infection and 3 months, 6 months and 1 year thereafter; red lines indicate positive cut-off values, negative cut-
83 off for NCP IgG. F) GM & 95% CI of NT₅₀ titers, Mean & 95% CI of S1-specific IgG and % inhibition in sVNT.
84 Abbr.: BAU, binding antibody units; CI, confidence interval; GM, Geometric Mean; NT₅₀, reciprocal sample
85 dilution resulting in 50% virus neutralization; NCP, nucleo capsid protein; RBD, SARS-CoV-2 receptor binding
86 domain; S1, SARS-CoV-2 Spike protein 1; sVNT, surrogate-virus neutralization test.
87

88 In order to define a threshold for the persistence of SARS-CoV-2-specific Abs, we correlated the
89 results from three months and one year post-infection. Importantly, NT₅₀ titers >1:10 at three
90 months after infection remained stable for one year ($r=0.861$, $p=0.0006$; Fig.2 A). Regarding S1-
91 specific IgGs, levels >60 BAU/ml also showed robust maintenance up to one year ($r=0.846$, $p=0.0009$;
92 Fig.2 B).



103 **Figure 2 A, B:** Relationship between log transformed Ab concentrations measured 3 months and 1 year post
104 infection for A) NT₅₀ titers 1:x ($r_s = 0.861$, $p=0.0006$), and B) S1-specific IgG in BAU/ml ($r_s = 0.846$, $p=0.0009$).
105 Grey lines indicate negative cut-off, red lines indicate potential thresholds for persistence after 3 months, and
106 green lines indicate retained Ab concentrations after 1 year.

107 The decline kinetics of infection-induced Abs (as also known for vaccine-induced Abs) are best
108 described by two-component models (2-5). The first component, starting after maximum Ab levels
109 are reached a few weeks after completed vaccination or resolved symptoms, is an initial fast decline.
110 The second component starts after a few months and is slowly declining (Fig. 1 F). We applied such a
111 model for the Abs measured with different assays, and observed a strong correlation of NT₅₀ titers
112 with S1-specific IgG and sVNT results for both the fast and slow decline component (NT₅₀, S1 IgG:
113 fast component: $r=0.596$, $p=0.041$; slow component: $r=0.571$, $p=0.047$; NT₅₀, sVNT: fast
114 component: $r=0.700$, $p=0.011$; slow component: $r=0.691$, $p=0.013$). Decline kinetics of NCP IgG ratios
115 were similar, while RBD-specific Ab ratios showed a different pattern with further increase up to 3
116 months in most subjects and then slight decline within one year.

117 Investigating the persistence of SARS-CoV-2 immunity on cellular level, we observed a clear positive
118 correlation of NT₅₀ titers, S1-specific IgG and circulating S1-specific memory B-cells one year after
119 infection. In contrast, S1-specific IFN- γ and IL-2 levels upon PBMC re-stimulation were higher in

120 subjects with lower Ab levels und fewer B memory cells, which did not apply for the NCP-specific
 121 cytokines (Table 1).

122

Subject Nr.	age range /years	gender	BAU/ml (1y)	NT_50 1:x (1y)	B cells (% of lymphos)	B-memory cells (% of B cells)	% S1-specific B memory	S1- & NCP-specific IL-2 (pg/ml) vs. baseline			S1- & NCP-specific IFN-γ (pg/ml) vs. baseline		
5	45-50	m	54.9	66	7.1	25.2	0.30	34	31	2	17	15	7
8	50-55	m	59.1	66	6.7	18.5	0.41	27	10	1	13	10	6
10	30-35	m	103.0	85	11.8	14.1	0.79	8	12	0	12	12	6
12	50-55	f	55.4	55	8.1	12.9	0.36	56	18	1	43	13	3
naive	40-45	m	--	--	4.2	25.9	0.01						

123

124 **Table 1:** S1-specific IgG in BAU/ml, NT_50 titers and respective percentages of B-cells, B memory cells and S1-
 125 specific B memory cells quantified by flow-cytometry for four COVID convalescent subjects and one SARS-CoV-2
 126 naïve control. S1- and NCP-specific IL-2 and IFN-γ concentrations (in pg/ml vs. baseline) measured by Luminex
 127 technology in supernatants of re-stimulated PBMC cultures (24h).

128

129 **Discussion:**

130 In order to determine for how long SARS-CoV-2-specific Abs are actually maintained, this study shows
 131 that measurement of Ab levels between 3 and 6 months after infection is crucial to assess Ab
 132 persistence, which is determined by both maximal initial Ab concentrations and decline kinetics. Also
 133 others report that SARS-CoV-2-specific immune parameters, e. g. RBD-specific Abs, their neutralizing
 134 activity and RBD-specific memory B-cells remain rather stable between 6 and 12 months after
 135 infection (6,7), but persistence has not been linked to NT_50 and S1-specific IgG decline kinetics
 136 and/or threshold.

137 We here propose S1-specific IgG concentrations of 60 BAU/ml three months post-infection as a
 138 potential threshold to predict maintenance of neutralizing Ab levels for one year. S1-specific IgG (in
 139 BAU) determined by ELISA are more accessible than NT assay results and might thus be more suitable
 140 for routine measurements (8). We further show that the frequency of persisting S1-specific B memory
 141 cells correlated with the level of maintained Abs in recovered subjects. A recent publication
 142 described a clear correlation between post infection memory B cells and subsequent vaccine induced
 143 antibody levels (9), indicating an immunological booster response originating from the previously
 144 established memory B cells.

145 Ab-mediated virus neutralization is not the only mechanism of protection against SARS-CoV-2
 146 infection and T-cell immunity in convalescent COVID-19 patients has been shown to maintain for 180
 147 days despite varying kinetics of the neutralizing Ab responses (e. g. slow/rapid waning or persistence)
 148 (10). Our data indicate that also one year after infection Abs are not necessarily accompanied by
 149 antigen-specific T cell recall responses, as more S1-specific T-cell proliferation (IL-2) was present in
 150 subjects retaining lower Ab levels.

151 Taken together, our data suggest that a threshold of Ab levels can be identified three months after
 152 (even) mild infection predicating persistence of SARS-CoV-2 specific Ab levels up to one year. Several
 153 mathematical models show that NT titers and S1 IgG binding Abs correlate with protective vaccine
 154 efficacy as well as that vaccine-induced Abs decline at similar rates as those following infection (11)

155 (12). Thus, our identified threshold might be helpful in assessing protection after vaccination, in
156 particular as long as no valid correlate of protection has been identified in vaccine trials.

157

158

159 **Materials & Methods:**

160 **Ab measurements:**

161 **SARS-CoV-2 neutralization test (NT) assay** was performed as previously described (13). **Anti-SARS-**
162 **CoV-2-QuantIVac-ELISA (IgG), SARS-CoV-2-NeutralISA surrogate virus neutralization test (sVNT)**
163 **and SARS-CoV-2 NCP-specific IgG ELISA**, all obtained from Euroimmune®, Euroimmun Medizinische
164 Labordiagnostik AG (Lübeck, Germany) were carried out according to the manufacturer's
165 instructions. **SARS-CoV-2 RBD-specific Abs** were determined with commercial ELISA for total Abs
166 (Beijing Wantai Biological Pharmacy Enterprise, Beijing, China) according to manufacturer's
167 instructions.

168 For detailed information on **SARS-CoV-2-specific Ab detection, quantification of S1-specific B**
169 **memory cells, S1-specific re-stimulation of PBMC and cytokine measurements** see Supplementary
170 Information.

171

172 **Author contributions:**

173 UW, HS, AW, EH, TRK, and EGS designed research; EGS, AR, AS and MRF performed research; VG,
174 JBH, RK and PM contributed new analytic tools; EGS and MK analyzed data; and EGS, MK and UW
175 wrote the paper.

176

177 **Acknowledgements:**

178 We would like to thank Sylvia Rudolf and Clemens Burtscher, MD (both Health Center Erste Bank,
179 Erste Bank, Vienna, Austria), as well as Ines Zwazl (BSc), Maria Orola (MSc), Santino Posch, all
180 associated with the Institute of Specific Prophylaxis and Tropical Medicine, Medical University of
181 Vienna, and Vanessa Maurer (BSc), Tatjana Matschi (BSc), Karin Schoiswohl (BSc), Barbara Schaar
182 (BSc) and Andrea Wendl (BSc), all associated with the Institute for Hygiene and Applied Immunology,
183 Medical University of Vienna, for their excellent administrative and technical support.

184 SARS-CoV-2 was sourced via EVAg (supported by the European Community) and kindly provided by
185 Christian Drosten and Victor Corman (Charité Universitätsmedizin, Institute of Virology, Berlin,
186 Germany).

187 The study received funding from the Austrian Federal Ministry of Education, Science and Research
188 within the research framework in relation to the coronavirus disease 2019 pandemic (GZ 20200225
189 104).

190

191 References:

- 192 1. Angelika Wagner AG, Johanna Ruff, Joanna Jasinska, Ute Scheickl, Ines Zwazl, Michael Kundi,
193 Hannes Stockinger, Maria R. Farcet, Thomas R. Kreil, Eva Hoeltl & Ursula Wiedermann.
194 Neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independently
195 of symptoms in adults. *Communications Medicine* 2021 doi [https://doi.org/10.1038/s43856-](https://doi.org/10.1038/s43856-021-00012-4)
196 021-00012-4.
- 197 2. Wiedermann G, Kundi M, Ambrosch F, Safary A, D'Hondt E, Delem A. Inactivated hepatitis A
198 vaccine: long-term antibody persistence. *Vaccine* 1997;**15**(6-7):612-5 doi 10.1016/s0264-
199 410x(96)00242-3.
- 200 3. Paulke-Korinek M, Kollaritsch H, Kundi M, Zwazl I, Seidl-Friedrich C, Jelinek T. Persistence of
201 antibodies six years after booster vaccination with inactivated vaccine against Japanese
202 encephalitis. *Vaccine* 2015;**33**(30):3600-4 doi 10.1016/j.vaccine.2015.05.037.
- 203 4. Van Damme P, Leroux-Roels G, Suryakiran P, Folschweiller N, Van Der Meeren O. Persistence
204 of antibodies 20 y after vaccination with a combined hepatitis A and B vaccine. *Human*
205 *vaccines & immunotherapeutics* 2017;**13**(5):972-80 doi 10.1080/21645515.2016.1274473.
- 206 5. Chappuis F, Farinelli T, Deckx H, Sarnecki M, Go O, Salzgeber Y, *et al.* Immunogenicity and
207 estimation of antibody persistence following vaccination with an inactivated virosomal
208 hepatitis A vaccine in adults: A 20-year follow-up study. *Vaccine* 2017;**35**(10):1448-54 doi
209 10.1016/j.vaccine.2017.01.031.
- 210 6. Wang Z, Muecksch F, Schaefer-Babajew D, Finkin S, Viant C, Gaebler C, *et al.* Naturally
211 enhanced neutralizing breadth against SARS-CoV-2 one year after infection. *Nature* 2021 doi
212 10.1038/s41586-021-03696-9.
- 213 7. Gallais F, Gantner P, Bruel T, Velay A, Planas D, Wendling MJ, *et al.* Evolution of antibody
214 responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. *EBioMedicine*
215 2021;**71**:103561 doi 10.1016/j.ebiom.2021.103561.
- 216 8. Krammer F. A correlate of protection for SARS-CoV-2 vaccines is urgently needed. *Nature*
217 *medicine* 2021 doi 10.1038/s41591-021-01432-4.
- 218 9. Goel RR, Apostolidis SA, Painter MM, Mathew D, Pattekar A, Kuthuru O, *et al.* Longitudinal
219 Analysis Reveals Distinct Antibody and Memory B Cell Responses in SARS-CoV2 Naive and
220 Recovered Individuals Following mRNA Vaccination. *medRxiv : the preprint server for health*
221 *sciences* 2021 doi 10.1101/2021.03.03.21252872.
- 222 10. Chia WN, Zhu F, Ong SWX, Young BE, Fong SW, Le Bert N, *et al.* Dynamics of SARS-CoV-2
223 neutralising antibody responses and duration of immunity: a longitudinal study. *The Lancet*
224 *Microbe* 2021;**2**(6):e240-e9 doi 10.1016/S2666-5247(21)00025-2.
- 225 11. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, *et al.* Neutralizing
226 antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2
227 infection. *Nature medicine* 2021 doi 10.1038/s41591-021-01377-8.
- 228 12. Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, *et al.* Evidence
229 for antibody as a protective correlate for COVID-19 vaccines. *Vaccine* 2021;**39**(32):4423-8 doi
230 10.1016/j.vaccine.2021.05.063.
- 231 13. Schwaiger J, Karbiener M, Aberham C, Farcet MR, Kreil TR. No SARS-CoV-2 Neutralization by
232 Intravenous Immunoglobulins Produced From Plasma Collected Before the 2020 Pandemic.
233 *The Journal of infectious diseases* 2020;**222**(12):1960-4 doi 10.1093/infdis/jiaa593.

234